Clinical research trials

CLL-002: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR. PI: Joseph Stilwill, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MM-002: A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM). PI: Suman Kambhampati, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE-004: OptimICE-PCR: De-Escalation of Therapy in EarlyStage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy. PI: Nisreen Haideri, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE-005: Randomized, Multicentre, Open-Label, Phase III study of Camizestrant + Capivasertib Versus Physician’s Choice of Endocrine-Based Therapy in Patients with Estrogen Receptor-Positive, HER2-Negative Inoperable Locally Advanced or Metastatic Breast Cancer Whose Disease has Progressed on Treatment with Aromatase Inhibitor + CDK4/6 inhibitor. PI: Anis Toumeh, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

WO45654: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled study evaluating the efficacy and safety of Inavolisib plus a CDK4/6 inhibitor and Letrozole versus placebo plus a CDK4/6 inhibitor and Letrazole in patients with endocrine-sensitive PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer. PI: Anis Toumeh, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Adjuvant WIDER: A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-toclinical practice patient population with HR+ HER2− early breast cancer. PI: Anis Toumeh, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Catalyst: Evaluates the safety and effectiveness of the Amulet LAA Occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. Principal Investigator: Dr. James Marcum

Facility: Overland Park Regional Medical Center, Research Medical Center

Champion AF: To determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation. Principal Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Overland Park Regional Medical Center, Research Medical Center

Define AF: Aims to improve the understanding of how data from the Reveal LINQ™ or LINQ II™ insertable cardiac monitor (ICM) can be used to guide the management of Afib. Principal Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center, Menorah Medical Center

Leadless II: Designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a single chamber pacemaker. Principle Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Overland Park Regional Medical Center

LUX-Dx PERFORM: To characterize the utilization of the remote programming feature of the Boston Scientific (BSC) Insertable Cardiac Monitor (ICM) device. The study will also collect data to characterize the performance of arrhythmia detection. Finally, data collected will be used to analyze and characterize the ICM system-related safety events. Principal Investigator: Dr. Scott Koerber

Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center

RELIEVE-HF: To provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System to improve clinical outcomes in a certain high-risk subset of symptomatic patients suffering from HF. Principal Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Overland Park Regional Medical Center, Research Medical Center

Solve CRT: To study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy. Principal Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Overland Park Regional Medical Center, Research Medical Center

HLX22-GC-301:A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer. PI: Joseph Stilwill, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

There are currently no research trials.

BELLA: A Phase 2 Study of Relacorilant in Combination with Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA). PI: Shawn Lybarger, DO

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN-005: A Phase 1B22 Baseky study of ACR-368 as monotherapy and in combiinatio with Gemcitabien in Adults with platinum-resistant ovarian carcinoma, Endometrial Adenocarcinoma and Urothelial carcinoma based on Acrivon Oncosignature status. PI: K. Shawn Lybarger, DO

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

There are currently no research trials.

DESTINY: For locally advanced or metastatic HER2-expressing Biliary Tract Cancer. Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab. PI: Anis Toumeh, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Lung04: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04). PI: Joseph Stilwill, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center